We have an update on the case of Parag Patel, the Park Ridge, Illinois cardiologist whom the Office of Research Integrity (ORI) said “engaged in research misconduct by directing or intimidating fellows and others to influence” test results so that patients would be eligible for a clinical trial.
A spokesperson for the clinical trial’s sponsor, the University of California, San Francisco (UCSF), tells us:
…the UCSF Institutional Review Board, as well as the independent Data Safety Monitoring Board for the study, will be reviewing the matter and making recommendations that might affect inclusion of data in the study. The number of patients enrolled from the Park Ridge site is a small fraction of the total participants enrolled to date.
More on the trial, from our Tuesday post:
The VEST trial “explores the hypothesis that wearable defibrillators can impact mortality by reducing sudden death during the first three months after a heart attack in persons with high risk for life-threatening arrhythmias,” according to its entry in ClinicalTrials.gov. It began recruiting 1,900 participants in 2008, and is expected to be complete in 2015.
Like Retraction Watch? Consider supporting our growth. You can also follow us on Twitter, like us on Facebook, add us to your RSS reader, and sign up on our homepage for an email every time there’s a new post.